Tackling “Undruggable Targets”: Why Are Molecular Glue Degraders Generating So Much Excitement?

In the field of innovative drug development, every major technological breakthrough has opened up new therapeutic possibilities. From small-molecule targeted therapies and monoclonal antibodies to the rapidly emerging field of targeted protein degradation, the boundaries of drug discovery continue to expand. Among protein degradation technologies, PROTACs (Proteolysis-Targeting Chimeras) have attracted significant attention in recent years. However, another emerging approach—Molecular Glue Degraders—is increasingly becoming a focal point for the global pharmaceutical industry.

Because of their potential to address the long-standing challenge of “undruggable targets,” molecular glues are widely regarded as one of the most promising innovations in targeted protein degradation and are viewed by many industry experts as a key platform for the next generation of drug discovery.

From Inhibition to Degradation: A New Paradigm in Drug Discovery

For decades, drug development has largely focused on inhibiting protein function. Traditional small-molecule drugs work by binding to specific pockets on a protein’s surface, thereby blocking its activity. However, many disease-related proteins lack obvious binding sites, making them inaccessible to conventional therapeutics. These proteins are commonly referred to as “undruggable targets.”

Examples include certain transcription factors, scaffold proteins, and cancer-driving proteins. Although they play critical roles in disease progression, they are difficult to modulate using traditional drug approaches. Studies suggest that currently approved drugs can directly target less than 20% of the human proteome, leaving a vast number of potential therapeutic targets unexplored.

The emergence of targeted protein degradation has changed this landscape. Rather than merely inhibiting protein activity, protein degradation technologies aim to eliminate disease-causing proteins altogether, addressing the root cause of disease at the protein level.

What Are Molecular Glue Degraders?

Molecular glue degraders are small molecules that induce a stable interaction between two proteins that would not normally bind to each other.

Simply put, they act like a drop of “glue,” bringing a target protein into proximity with an E3 ubiquitin ligase, the cellular machinery responsible for marking unwanted proteins for destruction. This interaction triggers ubiquitination of the target protein, leading to its degradation by the proteasome.

In fact, molecular glues are not an entirely new concept. The multiple myeloma drugs lenalidomide and pomalidomide were later found to alter the substrate recognition properties of the E3 ligase cereblon (CRBN), promoting the degradation of proteins such as IKZF1 and IKZF3. These drugs are now considered classic examples of molecular glue mechanisms.

This discovery demonstrated that artificially reshaping protein-protein interactions could create entirely new therapeutic opportunities.

How Do Molecular Glues Differ from PROTACs?

While PROTACs have driven rapid growth in the protein degradation field, molecular glues are believed to further expand the scope of this technology platform.

Key Differences Between Molecular Glues and PROTACs

Compared with PROTACs, one of the greatest advantages of molecular glues is their structural simplicity. Because they do not require the design of a complex bifunctional architecture, they more closely resemble traditional small-molecule drugs and often exhibit more favorable pharmacokinetic properties and oral bioavailability.

More importantly, molecular glues achieve degradation by creating new protein interactions, theoretically allowing them to access a much wider range of disease-related proteins that are beyond the reach of conventional therapies.

Why Are Global Pharmaceutical Companies Investing Heavily?

As the potential of molecular glues becomes increasingly evident, pharmaceutical companies worldwide are accelerating their investments in this area.

In recent years, companies such as Bristol Myers Squibb (BMS), Monte Rosa Therapeutics, Neomorph, Ambagon Therapeutics, and Ranok Therapeutics have devoted substantial resources to molecular glue research and development.

Among them, Bristol Myers Squibb is considered a pioneer in the field, leveraging decades of experience gained from lenalidomide and related compounds. Meanwhile, many biotechnology companies are focusing on discovering novel E3 ligases and identifying new therapeutic targets in hopes of developing the next generation of blockbuster drugs.

The capital markets have also shown strong enthusiasm. Over the past several years, multiple partnerships and licensing deals involving molecular glue technologies have reached hundreds of millions—or even billions—of dollars. Increasingly, investors view molecular glues as a potential growth engine for targeted protein degradation beyond PROTACs.

Current areas of focus include:

●  Oncology;

●  Autoimmune diseases;

●  Inflammatory disorders;

●  Neurodegenerative diseases;

●  Rare diseases.

As technology platforms continue to mature, the range of potential indications is expected to expand further.

Significant Challenges Remain

Despite their enormous promise, molecular glue degraders still face several important challenges.

The first is the complexity of discovery. Unlike PROTACs, which can often be developed through relatively rational molecular design, many molecular glues have historically been discovered serendipitously. Researchers frequently observe a biological effect first and then work backward to understand the underlying mechanism, introducing a significant degree of uncertainty into the development process.

The second challenge lies in screening efficiency. Identifying molecules capable of inducing specific protein-protein interactions among millions of compounds remains a major hurdle.

Additional challenges include:

●  Risks of off-target degradation;

●  Long-term safety validation;

●  Limited biomarker development;

●  Immature clinical translation pathways.

These obstacles mean that widespread commercialization of molecular glue degraders will take time, but they also represent important opportunities for future innovation.

Conclusion

From an industry perspective, targeted protein degradation is evolving from a single technology platform into a diverse ecosystem of therapeutic approaches. PROTACs demonstrated the feasibility of “degradation rather than inhibition,” while molecular glues are expanding the boundaries of that concept even further.

If PROTACs opened the door to the era of targeted protein degradation, molecular glues may be exploring what lies beyond it. With continued advances in artificial intelligence, structural biology, and high-throughput screening technologies, researchers are expected to discover novel molecular glues more efficiently and transform additional “undruggable targets” into actionable therapeutic opportunities.

Importantly, the impact of molecular glue therapeutics will not be limited to research and development. Once these drugs achieve commercial success, their influence is expected to extend across manufacturing, marketing, and pharmaceutical distribution. As more innovative therapies enter the market, the broader healthcare ecosystem will benefit from new growth opportunities. Pharmaceutical commerce and distribution companies, including Dengyue Pharmaceutical, may also benefit from the expanding pipeline and commercialization of innovative medicines.

For the global pharmaceutical industry, molecular glues represent more than a technological innovation—they signify a fundamental shift in drug discovery thinking. By moving from “finding binding pockets” to “rewiring protein relationships,” this new strategy is redefining the boundaries of modern therapeutics. As more candidates advance into clinical development, molecular glue degraders are poised to become a major pillar of the protein degradation field, bringing new hope to patients with cancer, autoimmune disorders, neurodegenerative diseases, and many other serious conditions.